Molecular Screening for Lynch Syndrome in Denmark

Vejle Hospital5,000 enrolled

Overview

A clinically applicably strategy for molecular screening for Lynch Syndrome is being implemented in Denmark. Based on sequential analysis with immunohistochemistry and methylation analysis, patients with possible hereditary colorectal cancer are identified. These patients are offered genetic risk assessment and counselling. The study hypothesis is that molecular screening will identify more patients with Lynch Syndrome than the family history alone. Prospective data collection is performed using established clinical databases.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Colorectal Cancer Lynch Syndrome HNPCC

Interventions

ObservationOTHER

Observation

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Histological diagnosis of colorectal adenocarcinoma * Diagnosed at one of the departments of pathology in Denmark Exclusion Criteria: * None

Locations (11)

Department of Pathology

Aalborg, Denmark

Department of Clinical Genetics

Aarhus, Denmark

Department of Pathology

Aarhus, Denmark

Department of Pathology

Esbjerg, Denmark

Outcomes

Primary Outcomes

Rate of Lynch Syndrome in a population of primary colorectal cancer

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.